RE:RE:RE:4+ months on $250K cashbencro, maybe the therapeutic laser division contributed profits in years past. For last year it consumed $3 million. Maybe the first quarter financials will show the division is breaking even in which case I would agree to keep it.
bencro wrote: 2b7f6fab ... Good observation about the tax credit.
As for the therapaeutic division, I differ of view. Because if that was true, and that TLT would have had no TLC-2000 division, and would have been only focused on oncology R&D since 2010 for example, we would have accumulated a huge debt, just like many other pure R&D biotechs. By the way, The TLC-2000 had a profit margins of 65%+ and the laser expertise we have also helps on the oncology side. With the CLT innovation, this will be even more appropriate to have this homemade expertise.